Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

BACKGROUND. The National Comprehensive Cancer Network (NCCN) guidelines for patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR, BRAF, ERBB2, and MET mutations; ALK, ROS1, and RET rearrangements; and MET amplification. We investigated the feasibility and utility of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Suh, James H., Johnson, Adrienne, Albacker, Lee, Wang, Kai, Chmielecki, Juliann, Frampton, Garrett, Gay, Laurie, Elvin, Julia A., Vergilio, Jo-Anne, Ali, Siraj, Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2016
Schlagworte:
Lung Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4912374/
https://ncbi.nlm.nih.gov/pubmed/27151654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0030
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge